• What level of therapeutic effect biologically validates an RNA target and how can we ensure robust validation to uncover the RNA’s true therapeutic potential

• Which criteria should guide the selection of RNA targets to ensure compatibility with small molecule binding and downstream functional binder discovery

• What structural motifs or folding are indicative of a druggable RNA target and how can we reliably identify them during early discovery